Only 20 full-company mergers or acquisitions occurred throughout the year, although asset acquisition deals were more common.

The agency made multiple decisions regarding coverage for diagnostic and laboratory testing that have affected the industry.

Last week, readers were most interested in Labcorp's acquisition of assets from MAWD, a CE mark for Roche's mass spec system, and features on Volition and Siemens Healthineers.

The companies said they plan to explore a range of questions including the clinical implementation of the Alzheimer's disease biomarker phosphorylated tau 217.

Consolidation within the industry also remained brisk as cost and reimbursement concerns provided acquisition opportunities for large national outfits.

The company consolidated its instrument lineup with its newer Atellica instruments and is phasing out support for Advia and Dimension branded analyzers through 2030.

NEW YORK – The US Department of Justice said last week that the owner and operator of a Texas clinical laboratory has been charged for his role in a $79 million respiratory pathogen panel (RPP) ...